Tokyo, April 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061264) titled 'A Study on Treatment Preferences Regarding Dosage Forms of Dementia Medications in Japan' on April 16.
Study Type:
Observational
Primary Sponsor:
Institute - Eisai Co., Ltd.
Condition:
Condition - MCI due to Alzheimer's disease (AD) or Mild AD dementia
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to quantify the factors and preferences influencing treatment selection for mild cognitive impairment and mild dementia due to Alzheimer's disease, expressed as utility values derived from the value judgments of the general population.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 40
years-old
Gender - Male and Female
Key inclusion criteria - Participants must meet all of the following conditions to be eligible for inclusion in the study:
1. Aged 40 years or older and younger than 80 years at the time of enrollment.
2. Provides informed consent to participate in the study.
3. Resides in Japan at the time of enrollment.
4. Has access to the necessary devices and a stable internet environment to complete the study online.
Key exclusion criteria - Participants who meet any of the following conditions will be excluded from the study:
1. Individuals for whom obtaining informed consent or completing the study procedures is deemed difficult due to insufficient comprehension ability, cognitive capacity, or Japanese language proficiency.
2. Individuals who are unable to personally participate in the survey.
Target Size - 2000
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 09 Day
Date of IRB - 2026 Year 04 Month 09 Day
Anticipated trial start date - 2026 Year 04 Month 20 Day
Last follow-up date - 2026 Year 05 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069873
Disclaimer: Curated by HT Syndication.
